Vergote I, et al. - In the INNOVATE (EF-22) Study, which was a phase 2, single arm clinical trial, researchers assessed the safety and efficacy of Tumor Treating Fields (TTFields) (200 kHz) combined with weekly paclitaxel (weekly for 8 weeks and then on days 1, 8, 15 of each subsequent 28 day-cycle; starting dose 80 mg/m²) in patients with recurrent, platinum-resistant ovarian carcinoma, with a focus on overall survival (OS), progression free survival (PFS) and RR. Based on the findings, TTFields in combination with weekly paclitaxel was proved to be a safe treatment option for patients with platinum-resistant recurrent ovarian cancer. The median PFS was 8.9 months, partial response was observed in 7 patients (25%) and the estimated clinical benefit rate was 71%.